A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

NCT ID: NCT00878800

Last Updated: 2015-07-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2012-10-31

Brief Summary

Open-label, multicentre, dose-escalation Phase I/II study to evaluate safety, efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with doxorubicin administered q 3 weeks in patients with advanced solid tumours. Once the Maximum Tolerable Dose has been established, up to a total of 20-40 patients with Soft Tissue Sarcoma may be enrolled at the MTD dose level to examine efficacy and safety in this specific patient population. The trial is stopped if no more than 2 responses are seen among the first 20 of these patients.

Conditions

Dose Escalation: Solid Tumors; MTD: Soft Tissue Sarcomas

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental: PXD101 and doxorubicin (BelDox)

5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV

Group Type: EXPERIMENTAL

PXD101

Intervention Type: DRUG

Administered in combination with doxorubicin (BelDox)

Doxorubicin

Intervention Type: DRUG

Administered in combination with PXD101 (BelDox)

Interventions

PXD101

Administered in combination with doxorubicin (BelDox)

Intervention Type: DRUG

Doxorubicin

Administered in combination with PXD101 (BelDox)

Intervention Type: DRUG

Other Intervention Names

PXD101 (Belinostat); Doxorubicin (Adriamycin)

Eligibility Criteria

Inclusion Criteria

1. Signed consent of an IEC (Independent Ethics Committee)-approved Information consent form

2. A. For the dose escalation phase: Patients with histological or cytological confirmed solid tumours (including sarcomas), for which there is no known curative therapy B. For the MTD expansion phase: Patients with an established diagnosis of soft tissue sarcoma in need of first line chemotherapy and with measurable disease

3. Performance status (ECOG) ≤ 2

4. Life expectancy of at least 3 months

5. Age ≥ 18 years

6. Acceptable liver, renal and bone marrow function including the following:

1. Bilirubin ≤ 1.5 times upper limit of normal (ULN)

2. AST ([Aspartate Amino Transferase]](SGOT), ALT (SGPT) and Alkaline Phosphatase ≤ 3 times upper limit of normal (if liver metastases are present, then ≤ 5 x ULN is allowed)

3. Serum creatinine ≤ 1.5 times upper limit of normal (ULN)

4. Leucocytes > 2.5 x 109/ L, neutrophils > 1.0 x 109/L, platelets > 100 x 109/L

5. Haemoglobin > 9.0 g/dL or > 5.6 mmol/l

7. Acceptable coagulation status: PT and APTT ([activated partial thromboplastin time ]) within ≤ 1.5 times upper limit of normal or in the therapeutic range if on anticoagulation.

8. A negative pregnancy test for women of childbearing potential. For men and women of child producing potential, the use of effective contraceptive methods during the study is required

9. Serum potassium within normal range

Exclusion Criteria

1. Treatment with investigational agents within the last 4 weeks

2. Prior anticancer therapy, within the last 3 weeks of trial dosing including chemotherapy, radiotherapy, endocrine therapy or immunotherapy

3. Co-existing active infection or any co-existing medical condition likely to interfere with trial procedures, including significant cardiovascular disease (New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable angina, congestive heart failure requiring therapy, unstable arrhythmia or a need for anti-arrhythmic therapy, or evidence of ischemia on ECG, marked baseline prolongation of QT/QTc ([corrected QT interval ]) interval, e.g., repeated demonstration of a QTc interval > 500 msec; Long QT Syndrome; the required use of concomitant medication on PXD101 infusion days that may cause Torsade de Pointes.

4. Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies

5. Concurrent second malignancy

6. History of hypersensitivity to doxorubicin

7. A. For dose escalation phase: More than two prior doses of anthracycline, more than three prior lines of chemotherapy given for metastatic disease B. For MTD expansion phase: Prior chemotherapy

8. Bowel obstruction or impending bowel obstruction

9. Known HIV positivity

10. LVEF ([left ventricular ejection fraction]) below normal range (45% by MUGA)

11. Presence of metastatic disease that, in the opinion of the investigator, would require palliative treatment within 4 weeks of enrolment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Spectrum Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: collaborator

Valerio Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

e-mail contact via enquires@topotarget.com

Role: STUDY_DIRECTOR

Valerio Therapeutics

Locations

Århus Hospital, Department of Oncology

Aarhus, , Denmark

Herlev Hospital, Department of Oncology

Herlev, , Denmark

The Royal Marsden NHS Trust, Cancer Research

Surrey, , United Kingdom

Countries

Denmark; United Kingdom

Other Identifiers

PXD101-CLN-14

Identifier Type: -

Identifier Source: org_study_id